Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Free Cash Flow (2023 - 2025)

Immunome (IMNM) has disclosed Free Cash Flow for 3 consecutive years, with -$56.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 45.26% year-over-year to -$56.4 million, compared with a TTM value of -$200.6 million through Dec 2025, down 76.59%, and an annual FY2025 reading of -$200.6 million, down 76.59% over the prior year.
  • Free Cash Flow was -$56.4 million for Q4 2025 at Immunome, down from -$40.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $24.0 million in Q1 2023 and bottomed at -$56.4 million in Q4 2025.
  • Average Free Cash Flow over 3 years is -$26.8 million, with a median of -$30.6 million recorded in 2024.
  • The sharpest move saw Free Cash Flow plummeted 341.68% in 2024, then fell 3.83% in 2025.
  • Year by year, Free Cash Flow stood at -$17.3 million in 2023, then crashed by 123.75% to -$38.8 million in 2024, then tumbled by 45.26% to -$56.4 million in 2025.
  • Business Quant data shows Free Cash Flow for IMNM at -$56.4 million in Q4 2025, -$40.5 million in Q3 2025, and -$50.1 million in Q2 2025.